IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Medical device maker Boston Scientific said on Monday it had agreed to buy Axonics for $3.7 billion, gaining access to devices used to improve bladder function. The deal marks Boston Scientific's ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics, Inc. after entering into a purchase agreement in January. Axonics, a publicly traded ...

Axonics presents with robust fundamentals and unit economics around its sacral neuromodulation segment. The company confirmed FY22 numbers above consensus, guides to FY23E revenues above the Street as ...

Boston Scientific Corp. agreed to pay $71 a share in cash for medical technology firm Axonics Inc., a maker of devices to treat urinary and bowel dysfunction. The purchase price comes to an equity ...

Axonics focuses on medical products to treat bladder and bowel dysfunction. The company, after the markets closed on Thursday, reported second-quarter revenue of $92.9 million, up 35%, year over year.

As of March 24, 2023, the average one-year price target for Axonics Modulation Technologies is $84.09. The forecasts range from a low of $65.65 to a high of $94.50. The average price target represents ...